News and Trends 22 Feb 2016
Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?
UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a phase III Osteoporosis trial, FRAME in partnership with Amgen. The drug showed 75% improvement (compared to placebo) and few side effects. UCB in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for an […]